Boehringer Ingelheim China posts robust business performance in 2021
China DailyThe Boehringer Ingelheim booth is seen at the fourth China International Import Expo in Shanghai in November. German multinational pharmaceutical company Boehringer Ingelheim has maintained strong growth in the Chinese market as all three major business units achieved outstanding performance last year to propel the company's overall rapid development in China, according to the company's annual result report for 2021 unveiled on Tuesday. Felix Gutsche, president and CEO of Boehringer Ingelheim Greater China, said the huge potential of the Chinese market and people's demand for high-quality healthcare products and services represent the biggest opportunities for Boehringer Ingelheim in China, and the company will continue to deeply engage with the Chinese market. According to the annual result report, Human Pharma was still the main revenue contributor, helping the company retain a leading position among multinational pharma companies in China.
History of this topic
Foreign pharma firms upbeat on China
China DailyDiscover Related
